Multivariate analyses of triple-negative breast cancer compare with non-triple-negative breast cancer: A multicenter retrospective study

AJBM crossMark

 

American Journal of BioMedicine Volume 10, Issue 1, pages 13-24
Nasser Ghaly Yousif *¹, Emilyn Duarte Conceição ²

Author Affiliations
*Correspondence author e-mail: yousif_ghaly@mu.edu.iq: ¹ Department of Medicine, Al muthanna Medical School, Iraq, ² Instituto de Microbiologia Paulo de Góes, Laboratório de Micobactérias, Brasil.

 

Abstract

Breast cancer is a heterogeneous disease of multiple subtypes with distinct morphologies and clinical implications. Triple negative breast cancer is associated with aggressive behavior and high risk of local and regional failure. The purpose of this study is to compare outcome of breast cancer for triple negative versus non-triple negative breast cancer. Population-based retrospective analysis was performed using the Surveillance, Epidemiology, and End Results (SEER) database. Female patients who had breast cancer from 2015 to 2021 were included in two centers and excluded patients’ files with incomplete data. Patients were divided into two group, triple negative breast cancer (TNBC) and non-TNBC. Clinical outcome, stages, types of treatment and its adverse events were compared. Also, and overall survival was calculated. A total of 105 patients with TNBC and 566 with non-TNBC were included in this retrospective study. The multivariate analysis showed that the tumor size and nodal involvement were independent predictors of negative events. While age at presentation, family history, grade had significant difference (p=0.005). Moreover, the number of locoregional failures, 5-year locoregional recurrence free, and mortalities were not significantly different (p=0.2). In conclusions: Our findings showed that the outcome of triple negative has worse survival than patients with non-TNBC and non-triple negative breast cancers and more aggressive at late stage.

Keywords: Breast cancer; Triple negative breast cancer; Non-triple-negative breast cancer

Copyright © 2022 Conceição ED et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article citationReferencesFull-Text/PDFBecome reviewer
The citation data is computed by the following citation measuring services:

Cited by (CrossRef)
Google Scholar

  1. Autier P, Boniol M, C La Vecchia, Vatten L, Gavin A, Hery C, Heanue M. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.
  2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007; 13:4429-4434.
  3. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007; 13:2329-2334.
  4. Tarantino P, Hamilton E, Tolaney SM, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J. Clin. Oncol. 2020; 38:1951-1962.
  5. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22:1151-1161. https://doi.org/10.1016/S1470-2045(21)00301-6
  6. Boissiere-Michot F, Jacot W, Massol O, Mollevi C, Lazennec G. CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. Cancers. 2021; 13:2328. https://doi.org/10.3390/cancers13102328
  7. Mansouri H, Alcaraz LB, Mollevi C, et al. Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers. 2020; 12:1244. https://doi.org/10.3390/cancers12051244
  8. Lehmann BD, Jovanovic B, Chen X, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE. 2016;11: e0157368.
  9. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. Journal of the National Cancer Institute. 2000; 92:1143-1150. https://doi.org/10.1093/jnci/92.14.1143
  10. Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008; 181:3099-107. https://doi.org/10.4049/jimmunol.181.5.3099
  11. Schettini F, Chic N, Braso-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer. 2021; 7:1. https://doi.org/10.1038/s41523-020-00208-2
  12. Vici P, Pizzuti L, Natoli C, et al. Triple positive breast cancer: a distinct subtype? Cancer Treat Rev. 2015; 41:69-76.
  13. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005; 11:4741-4748. https://doi.org/10.1158/1078-0432.CCR-04-2569
  14. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005; 11:4741-4748. https://doi.org/10.1158/1078-0432.CCR-04-2569
  15. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005; 11:4741-4748. https://doi.org/10.1158/1078-0432.CCR-04-2569
  16. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet. 2007; 369:29-36. https://doi.org/10.1016/S0140-6736(07)60028-2
  17. Lynch SP, Lei X, Chavez-MacGregor M, et al. Multifocality and multicentricity in breast cancer and survival outcomes. Annals of Oncology. 2012; 23:3063-3069. https://doi.org/10.1093/annonc/mds136
  18. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365:1273-1283. https://doi.org/10.1056/NEJMoa0910383
  19. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Breast. 2014; 23:489-502.
  20. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96:926-935. https://doi.org/10.1093/jnci/djh166
  21. Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Annals of Oncology. 2001; 12:997-1003. https://doi.org/10.1023/A:1011136326943  
  22. Yerushalmi R, Tyldesley S, Woods R, Kennecke HF, Speers C, Gelmon KA. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Annals of Oncology. 2012; 23:876-881.
  23. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Annals of Surgery. 2010; 252:426-432. https://doi.org/10.1097/SLA.0b013e3181f08f32
  24. Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006; 12:4614-4618. https://doi.org/10.1158/1078-0432.CCR-06-0248
  25. Creighton CJ, Massarweh S, Huang S, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008; 68:7493-7501. https://doi.org/10.1158/0008-5472.CAN-08-1404
  26. AH AI-Timimi. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: pathological correlation and prognostic indicators. American Journal of BioMedicine. 2014; 6:1229-1239.
  27. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. Journal of Clinical Oncology. 2004; 22:2303-2312. https://doi.org/10.1200/JCO.2004.09.062
  28. Zaky SS, Lund M, May KA, et al. The negative effect of triple-negative breast cancer on outcome after breastconserving therapy. Ann Surg Oncol. 2011; 18:2858-65. https://doi.org/10.1245/s10434-011-1669-4
  29. Seong MW, Kim KH, Chung IY, et al. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients. Breast Cancer Res Treat. 2014; 146:63-9. https://doi.org/10.1007/s10549-014-3006-7
  30. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347:1233-41. https://doi.org/10.1056/NEJMoa022152
  31. Al-Matwari M. Overexpression of Notch-1 induced tamoxifen resistance through down regulation of ESR1 in positive estrogen receptor breast cancer. Journal of clinical oncology 2012; 30(15_suppl):e11046-e11046.
  32. Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Annals of Surgery. 2013; 257:249-255. https://doi.org/10.1097/SLA.0b013e31827a8d17
  33. Adkins FC, Gonzalez-Angulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011; 18:3164-73. https://doi.org/10.1245/s10434-011-1920-z
  34. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 15:5379-88. https://doi.org/10.1158/1078-0432.CCR-09-0265
  35. Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. Journal of Clinical Oncology. 2010; 28:3929-3936. https://doi.org/10.1200/JCO.2010.28.2491
  36. Fitzal F, Riedl O, Wutzl L, et al. Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. Breast Cancer Research and Treatment. 2007; 103:45-52. https://doi.org/10.1007/s10549-006-9325-6
  37. Al Amran F. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC cardiovascular disorders 2011; 11 (1): 1-7.
  38. Luo C, Zhong X, Wang Z. Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort. Int J Biol Markers. 2019;34(1):41-46. https://doi.org/10.1177/1724600818824786
  39. Vici P, Pizzuti L, Natoli C. Triple positive breast cancer: a distinct subtype? Cancer Treat Rev. 2015; 41(2):69-76. https://doi.org/10.1016/j.ctrv.2014.12.005
  40. Xiao W, Zheng S, Yang A. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018; 10:5329-5338. https://doi.org/10.2147/CMAR.S176763
  41. Chen MT, Sun HF, Zhao Y. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Sci Rep. 2017; 7(1):9254. https://doi.org/10.1038/s41598-017-10166-8
  42. Prat A, Pineda E, Adamo B. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015; 24(suppl 2):S26-S35.
  43. Purdie CA, Quinlan P, Jordan LB. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014; 110(3):565-572. https://doi.org/10.1038/bjc.2013.756
  44. Itoh M, Iwamoto T, Matsuoka J. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat. 2014; 143(2):403-409. https://doi.org/10.1007/s10549-013-2763-z

For any technique error please contact us 

Who Can Become a Reviewer?
Any expert in the article's research field can become a reviewer with American Journal of Biomedicine. Editors might ask you to look at a specific aspect of an article,...

Find out more

Downloads: 304

  • Research Article
    http://dx.doi.org/10.18081/2333-5106/2022.10/13
    American Journal of BioMedicine Volume 10, Issue 1, pages 13-24
    Received November 28, 2021; revised January 19, 2022; accepted February 04, 2022; published February 28, 2022

    Downloads: 304
    PDF Download this Paper

    How to cite this article
    Yousif NG, Conceição ED. Multivariate analyses of triple-negative breast cancer compare with non-triple-negative breast cancer: A multicenter retrospective study. American Journal of BioMedicine 2022;10(1):13-24.
    Case Study
    1. Abstract
    2. Introduction
    3. Methods and patients
    4. Results
    5. Discussion
    6. References

    Article metric